Compare BRC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | LQDA |
|---|---|---|
| Founded | 1914 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2005 | 2020 |
| Metric | BRC | LQDA |
|---|---|---|
| Price | $91.82 | $30.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $38.60 |
| AVG Volume (30 Days) | 240.9K | ★ 1.8M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,144,698,000.00 | $13,996,000.00 |
| Revenue This Year | $6.90 | $993.31 |
| Revenue Next Year | $3.83 | $219.14 |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $62.70 | $11.26 |
| 52 Week High | $99.29 | $46.67 |
| Indicator | BRC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 33.46 |
| Support Level | $75.38 | $21.56 |
| Resistance Level | $99.29 | $36.07 |
| Average True Range (ATR) | 3.47 | 2.65 |
| MACD | -0.58 | -1.23 |
| Stochastic Oscillator | 42.98 | 11.10 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.